High-mobility group box-1 was released actively and involved in LPS induced depressive-like behavior

Journal of Psychiatric Research

Volumn 64, Issue , 2015, Pages 99-106

  Wu, Teng Yun ^a   Liu, Lei ^a   Zhang, Wei ^b   Zhang, Yi ^a   Liu, Yun Zi ^a   Shen, Xiao Liang ^a   Gong, Hong ^a   Yang, Yuan Yuan ^a   Bi, Xiao Ying ^b   Jiang, Chun Lei ^a   Wang, Yun Xia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CXCR4; Depression; Glycyrrhizic acid; GZA; HMGB1; HMGB1 protein; Lipopolysaccharide; LPS; POCD; TLR; TST; UCMS

Indexed keywords

GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DEPRESSION; IMMOBILITY; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TAIL SUSPENSION TEST; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; HUMAN; IMMOBILIZATION; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DEPRESSION; DISEASE MODELS, ANIMAL; GLYCYRRHIZIC ACID; HINDLIMB SUSPENSION; HMGB1 PROTEIN; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; TIME FACTORS;

EID: 84928209796     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.02.016     Document Type: Article

References (60)

1. Ader R., Cohen N. Behaviorally conditioned immunosuppression. Psychosom Med 1975, 37:333-340.
2. Andersson U., Tracey K.J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011, 29:139-162.
3. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. JExp Med 2000, 192:565-570.
4. Andrassy M., Volz H.C., Igwe J.C., Funke B., Eichberger S.N., Kaya Z., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117:3216-3226.
5. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994, 15:220-226.
6. Bourin M., Chenu F., Ripoll N., David D.J. Aproposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 2005, 164:266-269.
7. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011, 130:226-238.
8. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003, 361:2045-2046.
9. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
10. Datta S.C., Opp M.R. Lipopolysaccharide-induced increases in cytokines in discrete mouse brain regions are detectable using Luminex xMAP technology. JNeurosci Methods 2008, 175:119-124.
11. Duman R.S., Heninger G.R., Nestler E.J. Amolecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
12. Duman R.S., Monteggia L.M. Aneurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
13. Dunn A.J., Swiergiel A.H. Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 2005, 81:688-693.
14. Dunn A.J., Swiergiel A.H., de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev 2005, 29:891-909.
15. Farooq R.K., Isingrini E., Tanti A., Le Guisquet A.M., Arlicot N., Minier F., et al. Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation?. Behav Brain Res 2012, 231:130-137.
16. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531.
17. Garate I., Garcia-Bueno B., Madrigal J.L., Bravo L., Berrocoso E., Caso J.R., et al. Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. JNeuroinflammation 2011, 8:151.
18. Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002, 3:995-1001.
19. Girard J.P. Adirect inhibitor of HMGB1 cytokine. Chem Biol 2007, 14:345-347.
20. He H.J., Wang Y., Le Y., Duan K.M., Yan X.B., Liao Q., et al. Surgery upregulates high mobility group box-1 and disrupts the blood-brain barrier causing cognitive dysfunction in aged rats. CNS Neurosci Ther 2012, 18:994-1002.
21. Jiang W., Li J., Gallowitsch-Puerta M., Tracey K.J., Pisetsky D.S. The effects of CpG DNA on HMGB1 release by murine macrophage cell lines. JLeukoc Biol 2005, 78:930-936.
22. Kalinina N., Agrotis A., Antropova Y., DiVitto G., Kanellakis P., Kostolias G., et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004, 24:2320-2325.
23. Kang R., Chen R., Zhang Q., Hou W., Wu S., Cao L., et al. HMGB1 in health and disease. Mol Aspects Med 2014, 40C:1-116.
24. Kent S., Bluthe R.M., Kelley K.W., Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992, 13:24-28.
25. Kim I.D., Shin J.H., Kim S.W., Choi S., Ahn J., Han P.L., et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther 2012, 20:829-839.
26. Klune J.R., Dhupar R., Cardinal J., Billiar T.R., Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008, 14:476-484.
27. Kokkola R., Li J., Sundberg E., Aveberger A.C., Palmblad K., Yang H., et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003, 48:2052-2058.
28. Krahenbuhl S., Hasler F., Krapf R. Analysis and pharmacokinetics of glycyrrhizic acid and glycyrrhetinic acid in humans and experimental animals. Steroids 1994, 59:121-126.
29. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
30. Lucas K., Maes M. Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol 2013, 48:190-204.
31. Machado M., Iskedjian M., Ruiz I., Einarson T.R. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006, 22:1825-1837.
32. McDonald E.M., Mann A.H., Thomas H.C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 1987, 2:1175-1178.
33. Mollica L., De Marchis F., Spitaleri A., Dallacosta C., Pennacchini D., Zamai M., et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007, 14:431-441.
34. Niiranen A., Laaksonen R., Iivanainen M., Mattson K., Farkkila M., Cantell K. Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatr Scand 1988, 78:622-626.
35. Norman G.J., Karelina K., Zhang N., Walton J.C., Morris J.S., DeVries A.C. Stress and IL-1β contribute to the development of depressive-like behavior following peripheral nerve injury. Mol Psychiatry 2009, 15:404-414.
36. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14:511-522.
37. Oglodek E.A., Szota A., Just M.J., Mos D., Araszkiewicz A. Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression. Pharmacol Rep: P R 2014, 66:920-926.
38. Okuma Y., Liu K., Wake H., Zhang J., Maruo T., Date I., et al. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol 2012, 72:373-384.
39. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
40. Rauvala H., Rouhiainen A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med 2007, 7:725-734.
41. Ruscher K., Kuric E., Liu Y., Walter H.L., Issazadeh-Navikas S., Englund E., et al. Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke. JCereb Blood Flow Metab: Official J Int Soc Cereb Blood Flow Metab 2013, 33:1225-1234.
42. Saeedi M., Morteza-Semnani K., Ghoreishi M.R. The treatment of atopic dermatitis with licorice gel. JDermatolog Treat 2003, 14:153-157.
43. Schaper F., Heeringa P., Bijl M., Westra J. Inhibition of high-mobility group box 1 as therapeutic option in autoimmune disease: lessons from animal models. Curr Opin Rheumatol 2013, 25:254-259.
44. Schiraldi M., Raucci A., Munoz L.M., Livoti E., Celona B., Venereau E., et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. JExp Med 2012, 209:551-563.
45. Souery D., Papakostas G.I., Trivedi M.H. Treatment-resistant depression. JClin Psychiatry 2006, 67(suppl. 6):16-22.
46. Sulakhiya K., Kumar P., Jangra A., Dwivedi S., Hazarika N.K., Baruah C.C., et al. Honokiol abrogates lipopolysaccharide-induced depressive like behavior by impeding neuroinflammation and oxido-nitrosative stress in mice. Eur J Pharmacol 2014, 744:124-131.
47. Sun Q., Wu W., Hu Y.C., Li H., Zhang D., Li S., et al. Early release of high-mobility group box 1 (HMGB1) from neurons in experimental subarachnoid hemorrhage invivo and invitro. Jneuroinflammation 2014, 11:106.
48. Taniguchi N., Kawahara K., Yone K., Hashiguchi T., Yamakuchi M., Goto M., et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003, 48:971-981.
49. Ulloa L., Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006, 17:189-201.
50. Urbonaviciute V., Furnrohr B.G., Meister S., Munoz L., Heyder P., De Marchis F., et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. JExp Med 2008, 205:3007-3018.
51. Vacas S., Degos V., Tracey K.J., Maze M. High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages. Anesthesiology 2014, 120:1160-1167.
52. van Rossum T.G., Vulto A.G., Hop W.C., Brouwer J.T., Niesters H.G., Schalm S.W. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. JGastroenterol Hepatol 1999, 14:1093-1099.
53. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
54. Weber M.D., Frank M.G., Sobesky J.L., Watkins L.R., Maier S.F. Blocking toll-like receptor 2 and 4 signaling during a stressor prevents stress-induced priming of neuroinflammatory responses to a subsequent immune challenge. Brain, Behav Immun 2013, 32:112-121.
55. Xu H., Su Z., Wu J., Yang M., Penninger J.M., Martin C.M., et al. The alarmin cytokine, high mobility group box 1, is produced by viable cardiomyocytes and mediates the lipopolysaccharide-induced myocardial dysfunction via a TLR4/phosphatidylinositol 3-kinase gamma pathway. JImmunol 2010, 184:1492-1498.
56. Yang H., Wang H., Czura C.J., Tracey K.J. The cytokine activity of HMGB1. JLeukoc Biol 2005, 78:1-8.
57. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996, 711:163-174.
58. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.
59. Yu Z., Ohtaki Y., Kai K., Sasano T., Shimauchi H., Yokochi T., et al. Critical roles of platelets in lipopolysaccharide-induced lethality: effects of glycyrrhizin and possible strategy for acute respiratory distress syndrome. Int Immunopharmacol 2005, 5:571-580.
60. Zhang Y., Liu L., Peng Y.L., Liu Y.Z., Wu T.Y., Shen X.L., et al. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci Ther 2014, 20:119-124.